Precision took over a key hematology oncology study—the situation was critical
Data quality issues threatened the trial's integrity. The indications in this study required evaluating complex multifactorial disease response assessments which sites struggled to accurately assess and capture correctly. Missing baseline tumor assessment data, inconsistent data entry, and poorly constructed electronic data capture (EDC) forms inherited from previous CRO put the entire study at risk.
Complications in hematology oncology trial management
Several factors contributed to the study's state:
- Unsuitable Data Collection Tools: Pre-built forms in an older EDC edition didn't fit the specific needs of the included heme-onc indications.
- Complex Disease Assessment Requirements: The heme-onc indication studied in this study required understanding of the unique, complex tumor assessment categories making the overall assessment complicated. Sites struggled with accurate data capture and timing.
- Information Loss and Communication Issues: High turnover at both the CRO and sponsor levels led to critical information gaps.
- Evolving Regulatory Landscape: Ongoing changes in Sponsor guidance on assessing and reporting data for the studied heme-onc indications added complexity.
Why are heme-onc trials challenging?
Precision's approach to rescuing the hematology oncology trial
Faced with these challenges, Precision developed a comprehensive rescue strategy focused on thorough assessment, collaborative problem-solving, and innovative oversight.
Comprehensive gap analysis in AML trial rescue
- The first step was a detailed gap analysis to identify all issues within the study. This revealed significant problems in data collection tools, entry processes, and consistency. We presented these findings to the sponsor, emphasizing the need for collaborative decision-making.
Building collaboration in clinical trial rescue
- Recognizing the need for a united effort, we established close collaboration with the sponsor. Regular meetings and open communication ensured prompt issue resolution and rebuilt trust.
Implementing enhanced oversight in hematologic trials
- Precision's Centralized Monitoring department conducted holistic, patient-by-patient data reviews. This integration of scientific expertise was crucial for navigating the complexities of Hematology Oncology. We also created comprehensive tracking systems for regulatory management and start-up activities.
Lesion tracking, baselines, and standardization
| Re-establishing Baselines in Heme-Onc Data | Precision's Expertise in Lesion Tracking and Efficacy Assessment | Comprehensive Retraining and Standardization in Clinical Trials |
|
|
|
Data migration and EDC updates
To address historical errors and align with current assessment standards, we implemented significant EDC updates and data migrations, including:
- Updating case report forms for better data capture
- Standardizing response assessment procedures
- Implementing weekly data cleaning meetings
- Creating trackers for regulatory submissions and site activation
Precision teams drove significant improvement
- Restored Data Integrity: Meticulous clean-up efforts restored the study data's integrity, allowing the trial to progress.
- Rebuilt Sponsor Trust: Transparent communication and consistent results rebuilt the sponsor's confidence in data integrity and overall study management.
- Achieved Regulatory Compliance: Aligning the study with the latest FDA guidelines ensured accurate and compliant reporting, particularly crucial for the complexity of heme-onc indications.
- Ongoing Collaboration: The successful rescue led to continued collaboration on related studies, demonstrating the value of Precision's expertise.
Hematologic trial management learnings
This rescue mission provided valuable insights for managing complex hematologic trials:
- Early Intervention Prevents Complications: Identifying and correcting data issues early is crucial in study management.
- Specialized Training is Essential: Complex studies, especially in heme-onc, require specialized training for site staff and CRAs to ensure data accuracy.
- Collaboration is Fundamental: Close partnership between CROs and sponsors is vital, particularly in rescue scenarios.
- Customized EDC Prevents Issues: Tailoring EDC systems to specific study needs, especially for complex heme-onc indications, prevents downstream problems.
- Oversight Ensures Quality: Implementing oversight between trial staff and independent monitors provides crucial objectivity and early issue detection.
Advancing hematology oncology clinical trials: Lessons from a successful rescue
In hematology oncology rescue trials, expertise and innovation are key. The landscape is only getting more complex, but with the right approach – thorough assessment, close collaboration, and rigorous oversight – even the most challenging studies can be brought back from the brink.
Each trial, particularly those involving heme-onc diseases, requires a tailored approach beyond standard protocols. It's not just about following protocols; it's about understanding the unique challenges of each study and having the experience to navigate them.
The lessons from this rescue mission show what's possible when expertise meets innovation in clinical research. For sponsors facing similar challenges or aiming to prevent such issues, partnering with experienced CROs like Precision can steer even the most complex studies towards success.
Learn more about Precision's hematologic oncology trial expertise.
